Skip to main content
U.S. flag

An official website of the United States government

Search Results

Displaying 1 - 15 of 1171
Year PI Name PubMed/DOI Title Therapeutic Agent
Year: 2015 PI Name:Miao Jianting PubMed/DOI: 25611954 Inhibition of c-Jun N-terminal kinase activation reverses Alzheimer disease phenotypes in APPswe/PS1dE9 mice Therapeutic Agent(s):
  • SP600125
Year: 2015 PI Name:Zhang Wensheng PubMed/DOI: 25714973 Protective effect of notoginsenoside R1 on an APP/PS1 mouse model of Alzheimer's disease by up-regulating insulin degrading enzyme and inhibiting Aβ accumulation Therapeutic Agent(s):
  • Notoginsenoside R1 (NTR1)
Year: 2016 PI Name:Faghihi A. Mohammad PubMed/DOI: 27117003 The BET-bromodomain inhibitor JQ1 reduces inflammation and tau phosphorylation at Ser396 in the brain of the 3xTg model of Alzheimer’s disease Therapeutic Agent(s):
  • JQ1
Year: 2016 PI Name:Caraci Filippo PubMed/DOI: 26875816 The antineoplastic drug flavopiridol reverses memory impairment induced by Amyloid-β1-42 oligomers in mice Therapeutic Agent(s):
  • Flavopiridol
Year: 2016 PI Name: Kwon Jungkee PubMed/DOI: 27286707 6-Shogaol has anti-amyloidogenic activity and ameliorates Alzheimer’s disease via CysLT1R-mediated inhibition of cathepsin B Therapeutic Agent(s):
  • 6-Shogaol
Year: 2016 PI Name:Qin Chuan PubMed/DOI: 27240542 Cyanidin 3-O-β-glucopyranoside activates peroxisome proliferator-activated receptor-γ and alleviates cognitive impairment in the APPswe/PS1ΔE9 mouse model Therapeutic Agent(s):
  • Cyanidin 3-O-β-glucopyranoside
Year: 2017 PI Name:Schubert David PubMed/DOI: 28709449 A novel Alzheimer’s disease drug candidate targeting inflammation and fatty acid metabolism Therapeutic Agent(s):
  • CAD-031
Year: 2016 PI Name:Li Yan-Bing PubMed/DOI: 27518086 Fuzhisan ameliorates the memory deficits in aged SAMP8 mice via decreasing Aβ production and tau hyperphosphorylation of the hippocampus Therapeutic Agent(s):
  • Fuzhisan
Year: 2016 PI Name:Ehrhart Jared PubMed/DOI: 26414627 Biodistribution of infused human umbilical cord blood cells in Alzheimer’s disease-like murine model Therapeutic Agent(s):
  • Human umbilical cord blood cells (HUCBC)
Year: 2016 PI Name: Fisher Abraham PubMed/DOI: 26606130 AF710B, a novel M1/σ1 agonist with therapeutic efficacy in animal models of Alzheimer’s disease Therapeutic Agent(s):
  • AF710B (ANAVEX 3-71)
Year: 2016 PI Name:Tsai Kuen-Jer PubMed/DOI: 27264956 Gain of BDNF function in engrafted neural stem cells promotes the therapeutic potential for Alzheimer’s disease Therapeutic Agent(s):
  • BDNF-overexpressing Neural Stem Cells (BDNF-NSCs)
Year: 2016 PI Name:Bhaskar Kiran PubMed/DOI: 27974048 Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology Therapeutic Agent(s):
  • MW181
Year: 2016 PI Name:Shen Xu PubMed/DOI: 27569389 Small molecule LX2343 ameliorates cognitive deficits in AD model mice by targeting both amyloid β production and clearance Therapeutic Agent(s):
  • LX2343
Year: 2016 PI Name:Vrang Neils PubMed/DOI: 27421117 Long-term treatment with liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has no effect on β-amyloid plaque load in two transgenic APP/PS1 mouse models of Alzheimer's disease Therapeutic Agent(s):
  • Liraglutide
Year: 2016 PI Name:Pan Yan-Fang PubMed/DOI: 26992957 Exendin-4, a glucagon-like peptide 1 receptor agonist, protects against amyloid-β peptide-induced impairment of spatial learning and memory in rats Therapeutic Agent(s):
  • Exendin-4